16May 2022
Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma

Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines confer great protection against symptomatic and severe coronavirus disease (COVID-19) in healthy adults, but little is known for specialized patient populations despite billions of doses given worldwide. Asthma is one of the most common chronic respiratory diseases and affects approximately 25 million people in the United States alone. There are currently six U.S. FDA–approved biologic therapies for the treatment of asthma, with some that target cytokines critical for asthma pathogenesis, but inhibition of these cytokines may also negatively affect B cell to plasma cell differentiation, somatic hypermutation in the germinal centers, and long-lived plasma cell generation and maintenance potentially through eosinophil depletion (1–3). Despite animal studies showing decreased vaccine-induced humoral immunity without these cytokines (4, 5), there is a paucity of literature available in this patient population following SARS-CoV-2 vaccination.

  • #critical care

Like

Save

Share